2013-08-22 14:12:26 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Shenzhen Salubris Pharmaceuticals Co Ltd (2294) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Shenzhen Salubris Pharmaceuticals Co Ltd (2294). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Shenzhen Salubris Pharmaceuticals Co Ltd investor.
Report Summary: Shenzhen Salubris Pharmaceuticals Co Ltd is an above average quality company with a neutral outlook. Shenzhen Salubris Pharmaceuticals Co Ltd has strong business growth and is run by efficient management. The trend in Shenzhen Salubris Pharmaceuticals Co Ltd fair value exchange rate against its closest rated-competitor, Shan Dong Dong-E E-Jiao Co., Ltd., has been appreciating over the past 2 weeks. When compared to its closest competitor, Shenzhen Salubris Pharmaceuticals Co Ltd shows similar overvaluation and
is equally likely to outperform the market.
The report breaks down the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Shenzhen Salubris Pharmaceuticals Co Ltd for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.